Skip to main content

Table 2 mRNA levels upon treatment with combination of siRNAs against CAV1, ENO2, PKCα and DHFR.

From: Role of Caveolin 1, E-Cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells

A     
Treatment CAV1 ENO2 PKCα DHFR
siCAV1 + siENO2 + siPKCα 50.1 ± 4.3 50.5 ± 4.4 66.2 ± 2.6 82.9 ± 2.3
siCAV1 + siENO2 + siPKCα + siDHFR 37.7 ± 3.7 59.1 ± 0.8 47.6 ± 4.7 47.3 ± 1.2
400 nM NR-siRNA 96.8 ± 10.4 98.4 ± 0.5 96.3 ± 0.3 100.6 ± 13.4
B     
Treatment CAV1 ENO2 PKCα DHFR
siCAV1 + siENO2 + siPKCα 62.7 ± 0.2 44.20 ± 0.9 73.2 ± 4.9 97.7 ± 8.8
siCAV1 + siENO2 + siPKCα + siDHFR 45.4 ± 0.8 36.34 ± 4.2 40.6 ± 2.5 33.4 ± 3.8
400 nM NR-siRNA 99.1 ± 9.2 100.57 ± 15.9 103.2 ± 1.1 95.5 ± 10.2
  1. Treatments combining the siRNAs against CAV1, ENO2 and PKCα at 100 nM each were performed both in sensitive (A) and in resistant (B) HT29 cells. The mRNA levels for all three genes were determined at 48 hours of treatment. DHFR mRNA levels were also determined. Treatments combining 100 nM of the previous three siRNAs plus a siRNA against DHFR were also performed in both cell lines and mRNA levels for the four genes quantified by RT-Real-Time PCR. A non-related (NR) siRNA was used as negative control. Results are expressed as percentages of mRNA referred to untreated cells (mean ± SE) of triplicate experiments.